CN119487060A - 多重t细胞受体组合物、组合疗法以及其用途 - Google Patents

多重t细胞受体组合物、组合疗法以及其用途 Download PDF

Info

Publication number
CN119487060A
CN119487060A CN202380051389.XA CN202380051389A CN119487060A CN 119487060 A CN119487060 A CN 119487060A CN 202380051389 A CN202380051389 A CN 202380051389A CN 119487060 A CN119487060 A CN 119487060A
Authority
CN
China
Prior art keywords
hla
cell
tcr
cells
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380051389.XA
Other languages
English (en)
Chinese (zh)
Inventor
王伊帆
C·古勒
G·麦克比斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tisken Medical Co
Original Assignee
Tisken Medical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tisken Medical Co filed Critical Tisken Medical Co
Publication of CN119487060A publication Critical patent/CN119487060A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/427—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/084—Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/29—Multispecific CARs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Data Exchanges In Wide-Area Networks (AREA)
CN202380051389.XA 2022-05-02 2023-04-28 多重t细胞受体组合物、组合疗法以及其用途 Pending CN119487060A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202263337522P 2022-05-02 2022-05-02
US63/337522 2022-05-02
US202263342451P 2022-05-16 2022-05-16
US63/342451 2022-05-16
US202263413553P 2022-10-05 2022-10-05
US63/413553 2022-10-05
US202263423269P 2022-11-07 2022-11-07
US63/423269 2022-11-07
PCT/US2023/020338 WO2023215183A1 (en) 2022-05-02 2023-04-28 Multiplexed t cell receptor compositions, combination therapies, and uses thereof

Publications (1)

Publication Number Publication Date
CN119487060A true CN119487060A (zh) 2025-02-18

Family

ID=88646870

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380051389.XA Pending CN119487060A (zh) 2022-05-02 2023-04-28 多重t细胞受体组合物、组合疗法以及其用途

Country Status (12)

Country Link
US (1) US20250288675A1 (cg-RX-API-DMAC7.html)
EP (1) EP4519305A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025516264A (cg-RX-API-DMAC7.html)
KR (1) KR20250006149A (cg-RX-API-DMAC7.html)
CN (1) CN119487060A (cg-RX-API-DMAC7.html)
AU (1) AU2023265422A1 (cg-RX-API-DMAC7.html)
CA (1) CA3248253A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024016274A2 (cg-RX-API-DMAC7.html)
IL (1) IL316250A (cg-RX-API-DMAC7.html)
MX (1) MX2024013482A (cg-RX-API-DMAC7.html)
TW (1) TW202406569A (cg-RX-API-DMAC7.html)
WO (1) WO2023215183A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024005746A (es) * 2021-11-10 2024-07-19 Tscan Therapeutics Inc Peptidos inmunogenicos magea1, proteinas de union que reconocen peptidos inmunogenicos magea1, y usos de estos.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113595A2 (en) * 2004-05-19 2005-12-01 Avidex Ltd High affinity ny-eso t cell receptor
ES2635335T3 (es) * 2010-09-20 2017-10-03 Biontech Cell & Gene Therapies Gmbh Receptores de células T específicos de antígeno y epítopos de células T
NZ741124A (en) * 2012-07-27 2019-11-29 Univ Illinois Engineering t-cell receptors
JP6895975B2 (ja) * 2016-01-06 2021-06-30 ヘルス リサーチ インコーポレイテッドHealth Research, Inc. 組換えt細胞受容体を含む組成物及びライブラリー並びに組換えt細胞受容体を使用する方法
KR20190062505A (ko) * 2016-10-03 2019-06-05 주노 쎄러퓨티크스 인코퍼레이티드 Hpv-특이적 결합 분자
JP7289028B2 (ja) * 2018-09-05 2023-06-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 複数の主要組織適合遺伝子複合体分子に制限したny-eso-1-特異的t細胞受容体の組成物
WO2020167957A1 (en) * 2019-02-12 2020-08-20 Board Of Regents, The University Of Texas System High affinity engineered t-cell receptors targeting cmv infected cells
DE102019121007A1 (de) * 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
EP4010377A4 (en) * 2019-08-09 2023-09-06 A2 Biotherapeutics, Inc. CELL SURFACE RECEPTORS THAT RESPOND TO LOSS OF HETEROZYGOSIS

Also Published As

Publication number Publication date
EP4519305A1 (en) 2025-03-12
KR20250006149A (ko) 2025-01-10
IL316250A (en) 2024-12-01
EP4519305A4 (en) 2026-05-06
TW202406569A (zh) 2024-02-16
JP2025516264A (ja) 2025-05-27
WO2023215183A1 (en) 2023-11-09
CA3248253A1 (en) 2023-11-09
US20250288675A1 (en) 2025-09-18
CO2024016274A2 (es) 2024-12-09
AU2023265422A1 (en) 2024-10-24
MX2024013482A (es) 2024-12-06

Similar Documents

Publication Publication Date Title
US20230203124A1 (en) Methods of isolating t cell receptors having antigenic specificity for a cancer-specific mutation
CN110785432B (zh) Tcr和肽
EP3310805B1 (en) Pd-1-cd28 fusion proteins and their use in medicine
AU2016341529B2 (en) Methods for culturing cells and kits and apparatus for same
JP7491532B2 (ja) HvG疾患の処置における使用のためのCAR
KR20210057730A (ko) 조작 세포 및 이의 조성물 생성 방법
KR20200019126A (ko) 올리고머 입자 시약 및 이의 사용 방법
KR20200024770A (ko) γδ T 세포의 증식, 조성물 및 이의 사용 방법
KR20200046045A (ko) 유전자 조작된 세포를 제조하기 위한 방법 및 조성물
AU2014407540A1 (en) Methods of isolating T cells having antigenic specificity for a cancer-specific mutation
CN106459917A (zh) 分离、培养和遗传工程改造用于过继治疗的免疫细胞群的方法
KR20220158727A (ko) 종양 반응성 t 세포의 생체외 농축 및 확장 방법 및 이의 관련 조성물
KR20220002336A (ko) T 세포 치료제를 제조하기 위한 생체외 방법 및 관련 조성물 및 방법
KR20220122639A (ko) 조절제를 이용한 종양 반응성 t 세포 조성물의 제조 방법
US20180256645A1 (en) Cxcr6-transduced t cells for targeted tumor therapy
US20250288675A1 (en) Multiplexed t cell receptor compositions, combination therapies, and uses thereof
CN118909085A (zh) 识别wt1抗原短肽的t细胞受体(tcr)、多价tcr的复合物、药物组合物及用途
IL264855B2 (en) T-cell receptors and immunotherapy using them
EP4491630A1 (en) T-cell receptor for acute myeloid leukemia (aml)
RU2795454C2 (ru) Способы и композиции для получения генно-инженерных клеток
RU2808817C2 (ru) Способы получения из опухоли обогащенных популяций реактивных в отношении опухоли т-клеток
HK40064520A (en) Pd1-cd28 fusion proteins and their use in medicine
RU2778411C2 (ru) Способы культивирования клеток и наборы и устройство для них
HK40109405A (en) Pd1-cd28 fusion proteins and their use in medicine
WO2026055433A1 (en) Expansion of tumor-reactive t cells using anti-cd28 antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination